"Long COVID": More than a quarter of COVID-19 patients still symptomatic after 6 months

In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight months. Those findings are described this week in the open-access journal PLOS ONE by Milo Puhan and colleagues at the University of Zurich, Switzerland.

While initial public health responses to the SARS-CoV-2 virus focused on reducing the acute burden of COVID-19, a growing body of evidence indicates that the infection can also result in longer-term physical and mental health consequences. These long-term consequences, currently referred to as "post-COVID-19 syndrome" or "Long Covid" are of increasing concern for healthcare systems.

In the new study, researchers recruited 431 participants from within the contact tracing system in Zurich, Switzerland. All participants had tested positive for SARS-CoV-2 between February and August 2020, and completed an online questionnaire about their health a median of 7.2 months after their diagnosis. Symptoms had been present at diagnosis in 89% of the participants and 19% were initially hospitalized. Compared to individuals not participating in the study, participants were younger--with an average age of 47.

Overall, 26% of participants reported that they had not fully recovered at six to eight months after initial COVID-19 diagnosis. 55% reported symptoms of fatigue, 25% had some degree of shortness of breath, and 26% had symptoms of depression. A higher percentage of females and initially hospitalized patients reported not having recovered compared to males and non-hospitalized individuals. A total of 40% of participants reported at least one general practitioner visit related to COVID-19 after their acute illness. The authors say that their findings underscore the need for the timely planning of resources and patient services for post-COVID-19 care.

The authors add: "This cohort study based on a respresentative, population-based sample of SARS-CoV-2 infected individuals found that 26% did not fully recover within 6-8 months after diagnosis and 40% had at least one further healthcare contact related to COVID-19. These findings underline the need for the timely planning of healthcare resources and services tailored to the needs of individuals suffering from post-COVID-19 syndrome."

Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al.
Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study.
PLoS ONE 2021. doi: 10.1371/journal.pone.0254523

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...